Actuate Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Actuate Therapeutics Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
/ 
Frequently asked questions
To buy Actuate Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Actuate Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Actuate Therapeutics Inc. is ACTU:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Actuate Therapeutics Inc. has its primary listing on NASDAQ. You can trade Actuate Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Actuate Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Actuate Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Actuate Therapeutics Inc..